Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study

Journal of Endocrinological Investigation

Volumn 25, Issue 11, 2002, Pages 971-976

  Lombardi, Gaetano ^a   Colao, A ^a   Marzullo, P ^a   Biondi, B ^a   Palmieri, E ^a   Fazio, S ^a   Trischitta, V ^b   Battista, C ^b   Giovanni Rotondo, S ^b   Cozzi, R ^b   Barausse, M ^b   Faglia, G ^b   Arosio, M ^b   Giordano, G ^b   Giusti, M ^b   Mantero, F ^b   Arnaldi, G ^b   Martino, E ^b   Gasperi, M ^b   Sicolo, N ^b   Martini, C ^b   Valcavi, R ^b   Zini, M ^b   more..

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

Acromegaly; Arrhythmias; GH; Hypertrophy; IGF I; Lanreotide

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HOLTER MONITORING; HUMAN; ITALY; MALE; MORPHOLOGY; MULTICENTER STUDY; PREVALENCE; PROSPECTIVE STUDY; SLOW DRUG RELEASE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUPRAVENTRICULAR PREMATURE BEAT; SYSTOLE; SYSTOLIC BLOOD PRESSURE;

EID: 12244286036     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344070     Document Type: Article

References (30)

1. Saccà L., Cittadini A., Fazio S. Growth hormone and the heart. Endocr. Rev. 1994, 15: 555-573.
2. Isgaard J., Tivesten A., Friberg P., Bengtsson B.A. The role of the GH/IGF-I axis for cardiac function and structure. Horm. Metab. Res. 1999, 31: 50-54.
3. Colao A., Marzullo P., Di Somma C., Lombardi G. Growth hormone and the heart. Clin. Endocrinol. (Oxf.) 2001, 54: 137-154.
4. Fazio S., Cittadini A., Biondi B. et al. Cardiovascular effects of short-term growth hormone hypersecretion. J. Clin. Endocrinol. Metab. 2000, 85: 179-182.
5. McGuffin W.L. Jr., Sherman B.M., Roth J. et al. Acromegaly and cardiovascular disorders: A prospective study. Ann. Intern. Med. 1974, 81: 11-18.
6. Morvan D., Komajda M., Grimaldi A., Turpin G., Grosgogeat Y. Cardiac hypertrophy and function in asymptomatic acromegaly. Eur. Heart J. 1991, 12: 666-672.
7. Kahaly G., Olshausen K.V., Mohr-Kahaly S., et al. Arrhythmia profile in acromegaly. Eur. Heart J. 1992, 13: 51-56.
8. Fazio S., Cittadini A., Sabatini D. et al. Evidence for biventricular involvement in acromegaly: A Doppler echocardiographic study. Eur. Heart J. 1993, 14: 26-33.
9. Sicolo N., Bui F., Sicolo M. et al. Acromegalic cardiopathy: A left ventricular scintigraphic study. J. Endocrinol. Invest. 1993, 16: 123-127.
10. Fazio S., Cittadini A., Cuocolo A. et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J. Clin. Endocrinol. Metab. 1994, 79: 441-446.
11. López-Velasco R., Escobar-Morreale H.F., Vega B. et al. Cardiac involvement in acromegaly: Specific cardiopathy or consequence of systemic hypertension. J. Clin. Endocrinol. Metab. 1997, 82: 1047-1053.
12. Colao A., Cuocolo A., Marzullo P. et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study. J. Clin. Endocrinol. Metab. 1999, 84: 1518-1523.
13. Colao A., Baldelli R., Marzullo P. et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J. Clin. Endocrinol. Metab. 2000, 85: 193-199.
14. Thuesen L., Christensen S.E., Weeke J., Orskov H., Henningsen P. The cardiovascular effects of octreotide treatment in acromegaly: An echocardiographic study. Clin. Endocrinol. (Oxf.) 1989, 30: 619-625.
15. Pereira J., Rodriguez-Puras M.J., Leal-Cerro A. et al. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J. Endocrinol. Invest. 1991, 14: 17-23.
16. Lim M.J., Barkan A.L., Buda A.J. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann. Intern. Med. 1992, 117: 719-726.
17. Merola B., Cittadini A., Colao A. et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J. Clin. Endocrinol. Metab. 1993, 77: 790-793.
18. Tokgözoglu S.L., Erbas T., Aytemir K., Akalin S., Kes S., Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am. J. Cardiol. 1994, 74: 1072-1074.
19. Hradec J., Kral J., Janota T. et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am. J. Cardiol. 1999, 83: 1506-1509.
20. Baldelli R., Ferretti E., Jaffrain-Rea M.L. et al. Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients. J. Clin. Endocrinol. Metab. 1999, 84: 527-532.
21. Colao A., Marzullo P., Ferone D. et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR(r) in acromegaly. J. Clin. Endocrinol. Metab. 2000, 86: 3132-3140.
22. Colao A., Merola B., Ferone D., Lombardi G. Acromegaly. J. Clin. Endocrinol. Metab. 1997, 82: 2777-2781.
23. Colao A., Lombardi G. Growth hormone and prolactin excess. Lancet 1998, 352: 1455-1461.
24. Giustina A., Barkan A., Casanueva F.F. et al. Criteria for cure of acromegaly: A consensus statement. J. Clin. Endocrinol. Metab. 2000, 85: 526-529.
25. Sahn D.J., De Maria A., Kissio J., Weyman A. The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiography measurements. Circulation 1978, 58: 1072-1083.
26. Colao A., Cuocolo A., Marzullo P. et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J. Clin. Endocrinol. Metab. 1999, 84: 17-23.
27. Colao A., Cuocolo A., Marzullo P. et al. Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J. Clin. Endocrinol. Metab. 2001, 86: 1551-1557.
28. Haider A.W., Larson M.G., Benjamin E.S., Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J. Am. Coll. Cardiol. 1998, 32: 1454-1459.
29. Leong K.S., Mann P., Wallymahmed M., MacFarlane J.A., Wilding J.P. Abnormal heart rate variability in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 2000, 85: 628-633.
30. Bondanelli M., Ambrosio M.R., Franceschetti P., Margutti A., Trasforini G., Degli U. Diurnal rhythm of plasma cathecolamines in acromegaly. J. Clin. Endocrinol. Metab. 1999, 84: 2458-2467.